Downloads: 94

Files in This Item:
File Description SizeFormat 
s41598-019-39995-5.pdf1.18 MBAdobe PDFView/Open
Title: Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
Authors: Nishikawa, Keiichi
Oishi, Akio
Hata, Masayuki
Miyake, Masahiro  kyouindb  KAKEN_id
Ooto, Sotaro  kyouindb  KAKEN_id
Yamashiro, Kenji
Miyata, Manabu  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-7574-1749 (unconfirmed)
Tamura, Hiroshi  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-7740-2732 (unconfirmed)
Ueda-Arakawa, Naoko
Takahashi, Ayako  kyouindb  KAKEN_id
Kawashima, Yu
Tsujikawa, Akitaka  kyouindb  KAKEN_id
Author's alias: 西川, 慶一
大石, 明生
畑, 匡侑
三宅, 正裕
大音, 壮太郎
山城, 健児
宮田, 学
田村, 寛
上田, 奈央子
高橋, 綾子
川島, 祐
辻川, 明孝
Issue Date: 6-Mar-2019
Publisher: Springer Nature
Journal title: Scientific reports
Volume: 9
Thesis number: 3620
Abstract: Intravitreal injections of anti-vascular endothelial growth factor agents such as ranibizumab and aflibercept are the first-line treatment for neovascular age-related macular degeneration (AMD). However, data about long-term outcome in real-world clinical practice is scarce. We recruited 98 AMD patients and investigated four-year visual outcome. During the four years, 25 patients dropped out. The survivors received 7.0 ± 0.1 injections during the first year and 8.0 ± 7.4 injections in the following three years. The logarithm of minimum angle of resolution (logMAR) at baseline, year one, and year four was 0.28, 0.14 (P = 0.033), and 0.22 (P = 0.697), respectively. The gain of vision was not different among AMD subtypes (typical AMD, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation; P = 0.513) Among the investigated factors, the presence of external limiting membrane (ELM), the absence of vitreoretinal adhesion, and thicker choroid at baseline were associated with better logMAR values at year four (coefficient beta = −0.388, 0.201, and −0.001; P = 7.34 × 10⁻⁶; 0.01, and 0.028, respectively). In the present study, vision was retained at baseline level after the four-year treatment with aflibercept. The status of ELM, vitreoretinal adhesion, and choroidal thickness were predictive factors for final vision.
Rights: © The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
URI: http://hdl.handle.net/2433/237303
DOI(Published Version): 10.1038/s41598-019-39995-5
PubMed ID: 30842468
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.